METHODS: Reducing the dose delivered to the hippocampus below the therapeutic brain dose may increase the risk of hippocampal progression; thus, HA-WBRT may be associated with a risk of perihippocampal recurrence.
METHODS: Three patients with SCLC received HA-WBRT and developed intracranial failure during clinical follow-up; 3 relapsed with intracranial failure in the perihippocampal region after 12, 13, and 7 months, respectively.
RESULTS: Compared to the therapeutic brain dose of cases and the underdose region around the HA region, we matched MRI scans of intracranial failure and previous planning scans of simulation and found a deviation of the underdosed region within the perihippocampal failure of approximately 55% to 63%.
CONCLUSIONS: Perihippocampal failure is a rare clinical outcome in SCLC patients following HA-WBRT. Perihippocampal failure could be caused by an underdose of radiation or by the aggressiveness of the cancer itself. More research into this topic is encouraged.
方法:将传递给海马的剂量减少到低于治疗脑剂量可能会增加海马进展的风险;因此,HA-WBRT可能与海马周围复发的风险相关。
方法:3例SCLC患者接受HA-WBRT并在临床随访期间出现颅内衰竭;3例在12、13和7个月后复发并在海马周围区域出现颅内衰竭,分别。
结果:与病例的脑治疗剂量和HA区域周围的剂量不足区域相比,我们将颅内衰竭的MRI扫描与先前的模拟计划扫描进行了匹配,发现海马周围衰竭内剂量不足区域的偏差约为55%~63%.
结论:在HA-WBRT后SCLC患者中,海马周围衰竭是一种罕见的临床结局。海马周围衰竭可能是由于辐射剂量不足或癌症本身的侵袭性引起的。鼓励对该主题进行更多研究。